KRAS and familial pancreatic carcinoma: As mutations in KRAS are not only the major initiating event (25, 26), but are also required for maintenance of established tumors (27, 28), deployment of successful KRAS inhibitors for pancreatic cancer patients holds tremendous therapeutic promise for all pancreatic cancer patients, particularly those with distant disease who are in dire need of new therapeutic approaches.